1. Detection, verification, and quantification of adverse drug reactions;BH Stricker;BMJ,2004
2. Why drug safety should not take a back seat to efficacy;V Barbour;PLoS Med,2011
3. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects;JP Vandenbroucke;JAMA,2008
4. Committee for Proprietary Medicinal Products (1994) ICH topic E 1—population exposure: the extent of population exposure to assess clinical safety. CPMP/ICH/375/95. Available: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002747.pdf. Accessed 8 February 2013.
5. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (1994) ICH harmonised tripartite guideline: the extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions—E1. Available: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E1/Step4/E1_Guideline.pdf. Accessed 8 February 2013.